Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hbmp-700

HbMP-700

The World's First Safe and Efficacious Human Blood Substitute: HbMP-700, a Haemoglobin based oxygen carrier, based on bovine blood.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 HbMP-700 project word cloud

Explore the words cloud of the HbMP-700 project. It provides you a very rough idea of what is the project "HbMP-700" about.

stored    bears    malignancies    mio    good    700    global    care    adding    donors    severe    conducting    excellent    patients    haematological    donor    standard    slaughterhouse    cell    human    purification    military    match    manufacturing    sales    situation    annually    hbmp    weeks    proof    blood    infection    peak    treat    infections    supply    15nb    patented    subsequently    nearly    ery    leads    contamination    85    sufficient    feasibility    red    countries    lyophilized    unlimited    powder    first    voluntary    sme    market    clinical    gcp    types    world    compensate    bn    accidents    trial    critical    demand    transformed    humans    transfusions    representing    substitute    natural    conflicts    victims    healthcare    develops    technological    afford    months    frequent    few    surgery    bovine    gmp    economic    safety    markets    total    rbc    disasters    25    laboratory    regulatory    trials    plan    35    introduction    preclinical    cc    compliant    risk    shortages    source    patient    business    conduct    extracted   

Project "HbMP-700" data sheet

The following table provides information about the project.

Coordinator		 CC-ERY GMBH 

Organization address
address: ROBERT-ROSSLE-STRASSE 10
city: BERLIN
postcode: 13125
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.cc-ery.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CC-ERY GMBH DE (BERLIN) coordinator 50˙000.00

Map

 Project objective

CC-Ery GmbH develops HbMP-700, the world’s first substitute for human blood as a source for red blood cell (RBC) transfusions. 85 Mio. RBC transfusions are used p.a., representing a 10-15nb€ market. They are used to compensate for blood loss during surgery, treat patients with haematological malignancies, as well as victims of accidents, natural disasters, and military conflicts. The only source for RBC transfusions today are voluntary human blood donors. This leads to frequent supply shortages in the EU and other major healthcare markets. Donor blood must match patient blood. It can only be stored a few weeks, adding to the critical supply situation. Developing countries face a more severe situation as they cannot afford the standard of care of the developed world. In addition, human blood bears the risk of contamination with infections. HbMP-700 is extracted from bovine blood – a nearly unlimited, low cost supply source. It is transformed by a patented purification and manufacturing method to a lyophilized powder that is as effective as RBC transfusions from human blood, but bears no risk of infection, can be stored for months, and can be given to patients of all blood types. Bovine blood from one major EU slaughterhouse is sufficient to produce enough HbMP-700 to supply global demand for RBC transfusions. CC-Ery implemented the manufacturing method on a laboratory scale and is currently conducting preclinical trials, so far with excellent results. The objective of the SME Phase I project is to develop a business plan for the market introduction of HbMP-700. For this, a technological, regulatory, and economic feasibility analysis will be conducted. In Phase II, it is planned to build up a GMP (Good Manufacturing Practice) compliant manufacturing process and subsequently conduct a GCP (Good Clinical Practice) safety and proof of concept trial in humans. Total cost to market is estimated to be € 25-35 Mio. Peak sales are estimated to be more than € 1 bn. annually.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HBMP-700" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HBMP-700" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More